Skip to main content

Table 2 Incidence of KRAS mutations according to region

From: KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

Mutation Middle west n (%) Northeast n (%) North n (%) Southeast n (%) South n (%)
195 (100) 250 (100) 49 (100) 1,610 (100) 515 (100)
Gly12Asp (GGT > GAT) 79 (40.5) 99 (39.6) 15 (30.6) 587 (36.5) 174 (33.8)
Gly12Val (GGT > GTT) 48 (24.6) 53 (21.2) 16 (32.7) 397 (24.7) 124 (24.1)
Gly12Cys (GGT > TGT) 14 (7.2) 21 (8.4) 6 (12.2) 114 (7.1) 50 (9.7)
Gly12Ala (GGT > GCT) 12 (6.2) 14 (5.6) 1 (2) 90 (5.6) 32 (62)
Gly12Ser (GGT > AGT) 12 (6.2) 24 (9.6) 4 (8.2) 125 (7.8) 29 (5.6)
Gly12Arg (GGT > CGT) 6 (3.1) 5 (2) 2 (4.1) 16 (1) 5 (1)
Gly13Asp (GGC > GAC) 24 (2.3) 34 (13.6) 4 (8.2) 264 (16.4) 96 (18.6)
Gly13Cys (GGC > TGC) 0 0 0 11 (0.7) 2 (0.4)
Gly13Ser (GGC > AGC) 0 0 1 (2) 3 (0.2) 1 (0.2)
Gly13Val (GGC > GTT) 0 0 0 1 (0.1) 1 (0.2)
Gly13Arg (GGC > CGC) 0 0 0 2 (0.1) 1 (0.2)
Total/region (100) 33.5% 30.9% 34.5% 34.7% 32.0%
\